Singapore as an Expansion Gateway for Strategic Industries

Singapore can serve as a regional base for management, innovation, finance, and supply-chain oversight, while Vietnam provides manufacturing scale and market growth. This article examines which industries and operating models are best positioned to benefit from this complementary structure.

---

Singapore’s domestic market is small by regional standards, but its role in corporate decision-making extends far beyond local demand. Companies use the country for regional management, research, financing, product validation, and supply-chain control before deploying capital and operating capacity across Southeast Asia.

In 2025, headquarters, professional services, and research and development (R&D) projects accounted for most of Singapore’s S$8.9 billion in annual total business expenditure commitments. Technology companies contributed the largest share of headquarters investment, followed by consumer and professional services companies, according to the Singapore Economic Development Board (EDB).

These strengths do not benefit every business equally. Singapore’s costs favour companies whose regional decisions, technology, brands, or regulated products generate enough value to support a premium operating base. For companies with operations in Vietnam, the division of functions can be relatively clear: Singapore can host regional management, research, financing, and supply-chain oversight, while Vietnam supports manufacturing, software development, supplier expansion, and market growth. The clearest opportunities arise in sectors where this division creates a commercial advantage.

Advanced manufacturing and industrial technology

Singapore offers a clear value proposition for companies in:

• Semiconductors and electronics
• Precision engineering and robotics
• Aerospace
• Speciality chemicals
• Industrial technology

Singapore accounts for about one in 10 chips produced globally, one-fifth of global semiconductor equipment output, and 10 per cent of global aerospace maintenance, repair, and overhaul output. It also hosts more than 2,700 precision engineering and Electronic Manufacturing Services (EMS) providers.

Manufacturers can locate regional management, research, product design, prototyping, procurement, and technology deployment in Singapore. Key institutions supporting the transition from research to commercial use include:

• A*STAR’s Advanced Remanufacturing and Technology Centre, a public-private research platform with more than 95 consortium members;
• The Institute of Microelectronics
• The National Additive Manufacturing Innovation Cluster
• The Sectoral AI Centre of Excellence for Manufacturing

The model is particularly suited to companies requiring high precision, frequent design changes, or close coordination between engineers and suppliers. Semiconductor equipment makers, robotics developers, and aerospace component firms can use Singapore for pilot production, process qualification, and supplier validation before scaling up.

Vietnam can then provide the production scale, supplier depth, and cost base needed for regional growth. In May 2026, A*STAR ARTC and Becamex IDC signed an MOU on the establishment of the Vietnam Advanced Manufacturing Research Centre (VAMRC). Together with the expanding network of Vietnam–Singapore Industrial Parks, the proposed centre could strengthen links between Singapore’s research ecosystem and Vietnam’s industrial capacity.

Companies can retain product development, technical oversight, and regional procurement in Singapore while placing larger production footprints in Vietnam. Manufacturing that relies mainly on low labour costs is likely to gain less from this arrangement.

Biomedical sciences and MedTech

Pharmaceutical, biotechnology, diagnostics, medical-device, precision-health, and digital-health companies can benefit from Singapore’s concentration of scientific institutions, regulatory expertise, and commercial partners. Eight of the world’s top 10 biopharmaceutical companies conduct manufacturing or R&D activities in Singapore. The ecosystem supports intellectual property development, clinical validation, and regulatory strategy across Asian markets.

Singapore’s national platforms support different stages of biomedical product development:

• Diagnostics Development Hub – supports the development and commercialisation of diagnostic technologies
• Biologics Pharma Innovation Programme Singapore – advances biologics manufacturing and process innovation
• MedTech Catapult – provides product-development infrastructure covering design, development, verification, and validation

Expansion pathways vary by subsector. Diagnostic and medical device companies can benefit from clinical validation, quality assurance, and regulatory planning in Singapore, while digital-health firms can build partnerships with hospitals and regional distributors.

Once product specifications and quality systems are established, Vietnam can support selected manufacturing, software localisation, hospital integration, and service delivery at greater scale.

This model is best suited to proprietary or highly regulated products, where intellectual property, clinical evidence, and quality control can justify Singapore’s higher operating costs. Companies must still plan registration and market access separately for Vietnam and other ASEAN markets.

Digital technology and fintech

Enterprise software, artificial intelligence, cybersecurity, cloud services, digital payments, and fintech firms can use Singapore to reach regional customers and financial institutions. Singapore’s digital economy reached S$128.1 billion in 2024, equivalent to 18.6 per cent of GDP, according to the Infocomm Media Development Authority. By 2026, Singapore also hosted more than 60 AI centres of excellence established by technology and industrial companies.

Enterprise software companies such as US-based ServiceNow and AvePoint have used Singapore to develop regional capabilities. For firms selling to financial institutions and large companies, growth often depends on meeting requirements such as:

• Local contracting
• Security reviews
• Data governance
• Implementation support

A Singapore team can manage commercial and compliance requirements, while teams in Vietnam adapt integrations and delivery for individual clients.

A Singapore presence does not eliminate the need to assess licensing, data, payment, and consumer requirements in each Southeast Asian market. Digital firms must still adapt their products, pricing, and distribution strategies to local conditions.

Consumer brands and food and beverage businesses

Premium retail, beauty, wellness, jewellery, fashion, hospitality, and differentiated food brands can use Singapore as a controlled test market. Its affluent and culturally diverse consumers allow companies to assess:

• Product preferences
• Brand positioning
• Service formats
• Experiential concepts

From 2022 to September 2025, EDB secured more than 50 new investment commitments from consumer comp…, spanning headquarters, R&D, and retail-testbed activities.

Pandora opened a regional headquarters in Singapore to manage branding, marketing, market development, and operations across Asia. Coach tested hospitality through café, coffee shop, and restaurant concepts, while On and Alo opened flagship stores. Blue Bottle Coffee opened its first café in Singapore in April 2025. These examples show how a physical presence can generate market insight and visibility beyond direct store revenue.

Companies should treat market testing in Singapore as a structured commercial exercise rather than a branding showcase. Useful indicators include:

• Customer acquisition costs
• Repeat purchases
• Average transaction value
• Channel performance
• Willingness to pay

Before entering Vietnam, brands should retest price points, store formats, digital sales channels, and product ranges against local income levels and consumer behaviour.

The model suits well-capitalised brands with distinctive products, premium margins, and concepts that can scale across several markets. Brands competing mainly on price or domestic sales volume may struggle to justify Singapore’s high operating costs.

Trade logistics and regional supply-chain management

Manufacturers, commodity traders, speciality distributors, and cold-chain operators can use Singapore to coordinate:

• Regional procurement
• Treasury and trade finance
• Inventory and supplier governance
• Risk monitoring
• Distribution

Singapore is connected to more than 600 ports worldwide and has 29 implemented free trade agreements covering over 85 per cent of global GDP. These links support its role as a regional supply-chain control centre.

Companies should also assess whether Singapore improves working capital and risk control, rather than focusing only on transport connectivity. A regional team can compare supplier performance, consolidate purchasing, oversee trade finance, and redirect orders when disruption affects a Vietnamese factory or shipping route. This model particularly benefits companies with fragmented supplier networks, temperature-sensitive products, or significant exposure to currency and inventory risks.

For companies operating in Vietnam, this structure gives regional leaders visibility across factories, ports, distributors, and suppliers and supports faster responses to disruption. Singapore adds value through decision-making and network management, rather than by absorbing every physical activity.

Which businesses are best positioned to gain

Sector alone should not determine whether a company expands through Singapore. The country adds the most value when a business needs regional authority, specialist talent, research partnerships, external capital, intellectual property protection, or coordination across several markets. It offers less advantage to companies serving one national market or competing mainly on labour and operating costs.

For companies with operations or expansion plans in Vietnam, three models stand out:

• Regional headquarters in Singapore with commercial or production operations in Vietnam. This model suits diversified manufacturers and service providers that need one leadership team to allocate capital and coordinate several markets.
• Research and commercialisation in Singapore with manufacturing in Vietnam. This structure fits industrial, biomedical, and technology companies that must protect intellectual property and validate products before scaling output.
• Product testing in Singapore followed by rollout in Vietnam and other ASEAN markets. This option works for consumer and digital businesses that need market evidence before committing to wider distribution.

The strongest model assigns each location a distinct function, allowing Singapore to perform a specialised regional role without duplicating the company’s wider operating footprint.